Comunicati Stampa
Elettronica

Carl Zeiss Introduces the First Trifocal Preloaded True-MICS IOL for Enhanced Intermediate Vision

"We would like to assist our customers in optimally addressing the challenges of surgical cataract and presbyopia correction," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. "With the AT LISA tri trifocal IOL this means that patients are provided with the most natural post-operative vision possible without being reliant on eyeglasses."
WELWYN, (informazione.news - comunicati stampa - elettronica)

"We would like to assist our customers in optimally addressing the challenges of surgical cataract and presbyopia correction," says Dr. Ludwin Monz , President and CEO of Carl Zeiss Meditec AG. "With the AT LISA tri trifocal IOL this means that patients are provided with the most natural post-operative vision possible without being reliant on eyeglasses."

Functional vision in all light conditions and lower visual disturbance

Based on the established AT LISA platform, the AT LISA tri is designed to produce more satisfying and predictable visual outcomes to active patients and maximized pupil independency. The IOL features a unique asymmetrical light distribution between the three different foci - 50 percent far, 20 percent intermediate, 30 percent near. Additionally the light energy transmittance is increased for a maintained contrast sensitivity rate and lower visual disturbance. "My patients report significantly less halos and glare with the AT LISA tri, even when directly questioned about these phenomena," reports Dr. Elisabeth Frieling-Reuss , ophthalmologist in Munich, Germany , about her experiences.

AT LISA tri can provide enhanced intermediate vision performance with its addition of +1.66 diopters compared to apodized bifocal or convoluted trifocal IOLs, even under poor light conditions.

Simple and safe implantation

AT LISA tri is suitable for microincision cataract surgery (MICS) to avoid intraoperative induced astigmatism and reduces higher order aberrations. The preloaded AT LISA tri 839MP combined with the innovative BLUEMIXS 180 injector allows easy and safe implantation through an incision of 1.8 millimeters.

To maintain lasting visual quality and prevent posterior capsular opacification (PCO), AT LISA tri features an anti-PCO posterior profile. This reinforces the effect of the square edges for double prevention of PCO formation.

With the addition of AT LISA tri to the ZEISS MICS Platform, Carl Zeiss Meditec continues to provide an even more complete and innovative range of products for micro incision cataract surgery.

For more information visit http://www.meditec.zeiss.com/lisa-tri

Contact: +44(0)1707-871-333

Email: customercare@zeiss.co.uk

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili